Eap, Chin Bin

 
Title Year Hits Downloads
Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances 2018 12 3
Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study 2018 14 0
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts 2016 130 0
Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l’évaluation de la balance bénéfice-risque 2016 92 3
Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments 2015 200 1
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments 2015 208 0
Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions 2015 151 1
Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression 2015 194 48
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance 2014 190 0
Blood pressure in relation to coffee and caffeine consumption 2014 178 0
Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population 2013 256 0
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women 2013 242 0
Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension 2012 296 0
Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring 2011 271 2
The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution 2010 268 1
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone 2010 337 2
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety 2010 231 1
Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study 2009 274 7
Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS 2009 279 0
Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples 2009 209 0
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals 2009 257 1
Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit 2008 170 0
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response 2008 297 1
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: Evidence of a safer cardiac profile of (R)-methadone 2008 257 5
Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives 2008 306 195
5319 271